Skip to main navigation
Skip to search
Skip to main content
Mayo Clinic Home
Home
Profiles
Departments/Divisions
Grants
Research output
Prizes
Search by expertise, name or affiliation
New drugs for the treatment of myelofibrosis
Ruben A. Mesa
Hematology/Oncology
Research output
:
Contribution to journal
›
Review article
›
peer-review
8
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'New drugs for the treatment of myelofibrosis'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
New Drugs
100%
Myelofibrosis
100%
Anemia
33%
Medical Therapy
22%
Splenomegaly
22%
Targeted Agents
11%
Treatment Refractory
11%
Hematologist
11%
Debilitating Disease
11%
Associated Symptoms
11%
Immunomodulation
11%
Disease Manifestations
11%
Thrombocytopenia
11%
Hypomethylation
11%
Polycythemia Vera
11%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
11%
Constitutional Symptoms
11%
Essential Thrombocythemia
11%
JAK2 Inhibitor
11%
Blast Phase
11%
Primary Myelofibrosis
11%
Cytopenia
11%
Constitutional Change
11%
Massive Splenomegaly
11%
Complementary Benefit
11%
Medicine and Dentistry
Myelofibrosis
100%
Anemia
33%
Splenomegaly
33%
Combination Therapy
22%
Immunomodulation
11%
Constitutional Symptoms
11%
Essential Thrombocythaemia
11%
Myeloid metaplasia
11%
Polycythemia vera
11%
Thrombocytopenia
11%
Janus Kinase 2 Inhibitor
11%
Cytopenia
11%
Allogeneic Stem Cell Transplantation
11%
Diseases
11%